You are here

Prospective study of γ' fibrinogen and incident venous thromboembolism: The Longitudinal Investigation of Thromboembolism Etiology (LITE).

TitleProspective study of γ' fibrinogen and incident venous thromboembolism: The Longitudinal Investigation of Thromboembolism Etiology (LITE).
Publication TypeJournal Article
Year of Publication2016
AuthorsFolsom, AR, Tang, W, George, KM, Heckbert, SR, MacLehose, RF, Cushman, M, Pankow, JS
JournalThromb Res
Volume139
Pagination44-9
Date Published2016 Mar
ISSN1879-2472
Abstract<p><b>INTRODUCTION: </b>Epidemiological studies generally have not found plasma total fibrinogen to be a risk factor for venous thromboembolism (VTE), but several have reported associations between variants in the fibrinogen gamma gene (FGG) and VTE. A case-control study in whites suggested plasma γ' fibrinogen concentration may be associated inversely with VTE, but this was not replicated in African Americans.</p><p><b>OBJECTIVE: </b>To examine the prospective association between γ' fibrinogen concentrations and occurrence of VTE.</p><p><b>METHODS: </b>We used the Longitudinal Investigation of Thromboembolism Etiology (LITE), involving two pooled population-based cohorts in the United States including 16,234 participants. The cohorts comprised white and African American men and women, aged 50years and older at study onset in the early 1990s. We identified VTEs during follow-up and documented they met standardized diagnostic criteria.</p><p><b>RESULTS: </b>During two decades of follow-up, neither γ' fibrinogen nor total fibrinogen nor their ratio was associated with VTE overall (n=521 VTEs), in subgroups defined by race, or in other subgroups. In both race groups, the minor allele of FGG rs2066865 was associated with lower γ' fibrinogen concentrations, but this allele was not associated with VTE.</p><p><b>CONCLUSIONS: </b>A lower plasma concentration of γ' fibrinogen in healthy adults does not appear to increase VTE risk.</p>
DOI10.1016/j.thromres.2016.01.008
Alternate JournalThromb. Res.
PubMed ID26916295
PubMed Central IDPMC4769380
Grant ListHHSN268200800007C / HL / NHLBI NIH HHS / United States
HHSN268200800007C / / PHS HHS / United States
HHSN268201100005C / HL / NHLBI NIH HHS / United States
HHSN268201100005C / / PHS HHS / United States
HHSN268201100006C / HL / NHLBI NIH HHS / United States
HHSN268201100006C / / PHS HHS / United States
HHSN268201100007C / HL / NHLBI NIH HHS / United States
HHSN268201100007C / / PHS HHS / United States
HHSN268201100008C / HL / NHLBI NIH HHS / United States
HHSN268201100008C / / PHS HHS / United States
HHSN268201100009C / HL / NHLBI NIH HHS / United States
HHSN268201100009C / / PHS HHS / United States
HHSN268201100010C / HL / NHLBI NIH HHS / United States
HHSN268201100010C / / PHS HHS / United States
HHSN268201100011C / HL / NHLBI NIH HHS / United States
HHSN268201100011C / / PHS HHS / United States
HHSN268201100012C / HL / NHLBI NIH HHS / United States
HHSN268201100012C / / PHS HHS / United States
HHSN268201200036C / HL / NHLBI NIH HHS / United States
HHSN268201200036C / / PHS HHS / United States
HL0597367 / HL / NHLBI NIH HHS / United States
N01HC55222 / HC / NHLBI NIH HHS / United States
N01HC55222 / HL / NHLBI NIH HHS / United States
N01HC85079 / HC / NHLBI NIH HHS / United States
N01HC85079 / HL / NHLBI NIH HHS / United States
N01HC85080 / HC / NHLBI NIH HHS / United States
N01HC85080 / HL / NHLBI NIH HHS / United States
N01HC85081 / HC / NHLBI NIH HHS / United States
N01HC85081 / HL / NHLBI NIH HHS / United States
N01HC85082 / HC / NHLBI NIH HHS / United States
N01HC85082 / HL / NHLBI NIH HHS / United States
N01HC85083 / HC / NHLBI NIH HHS / United States
N01HC85083 / HL / NHLBI NIH HHS / United States
N01HC85086 / HC / NHLBI NIH HHS / United States
N01HC85086 / HL / NHLBI NIH HHS / United States
R01 HL059367 / HL / NHLBI NIH HHS / United States
R01AG023629 / AG / NIA NIH HHS / United States
T32 HL007779 / HL / NHLBI NIH HHS / United States
U01HL080295 / HL / NHLBI NIH HHS / United States